{"entity":{"id":"tina-cascone","kind":"person","name":"Tina Cascone","aka":[],"tldr":"Led CheckMate 77T, one of the perioperative immunotherapy trials that changed how operable lung cancer is treated.","summary":"Tina Cascone was principal investigator of CheckMate 77T, which showed neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab improves event-free survival in resectable NSCLC, and led the NEOSTAR window trials that defined pathological response endpoints. Her laboratory studies the immune correlates of response to neoadjuvant therapy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cascone%20T%5BAuthor%5D%20neoadjuvant%20nivolumab"}],"tags":["lung","neoadjuvant","immunotherapy"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["checkmate-816","keynote-671"],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-816-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Neoadjuvant immunotherapy","Perioperative NSCLC therapy","Translational immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cascone%20T%5BAuthor%5D%20neoadjuvant%20nivolumab"}],"papers":[{"title":"Perioperative nivolumab in resectable lung cancer (CheckMate 77T)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2311926"},{"title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","journal":"Nature Medicine","year":2021,"doi":"10.1038/s41591-020-01224-2"},{"title":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"}]},"route":"/people/tina-cascone/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/"},{"id":"keynote-671","kind":"trial","name":"KEYNOTE-671","route":"/trials/keynote-671/"}],"paper":[{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/"}]}}